Investment, Funding & Disinvestments

McKesson expects the acquisition to strengthen its oncology and multi-specialty strategy while broadening the services it provides to biopharmaceutical companies.

Biohaven is currently evaluating the therapy in the Phase II/III RISE3 study, with results expected in the second half of 2026.

Minapharm’s candidate is the fifth Bundibugyo-specific vaccine supported by CEPI as the Democratic Republic of the Congo (DRC) responds to a rapidly escalating outbreak.

WHO Regional Director for Africa Dr. Mohamed Yakub Janabi presented the strategy during a session chaired by Ethiopia’s Minister for Health, Dr. Mekdes Daba.

Hanmi is developing the HM17321 therapy as a potential first-in-class treatment that could promote weight loss while helping preserve lean body mass.

Seralutinib is an investigational treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The company’s focus on both non-potent and high-potency APIs reflects the range of projects handled at the site, from conventional small-molecule development to programs requiring additional containment and specialized handling.

France and its partners supported the construction and equipping of the clinic before handing it over to the Government of Liberia, the Ministry of Health, and the County Health Team.

Construction of the Hillsboro facility is expected to create about 200 jobs, with workers remaining on site through the project’s anticipated completion in 2031.

Siemens Healthineers will contribute US$5.4 million in cost sharing, bringing the total potential investment to US$36.5 million.